Description

Doxorubicin (doxorubicin) concentrate for infusions 2 mg/ml. 5 ml. (10 mg.) vial №1

Ingredients:

Each ml contains 2 mg of Doxorubicin hydrochloride.

Dosage:

The dosage is individualized based on the patient’s condition, weight, and overall health. It is administered intravenously by a healthcare professional.

Indications:

Doxorubicin is indicated for the treatment of various types of cancers, including breast cancer, lung cancer, and leukemia. It works by stopping the growth of cancer cells.

Contraindications:

This medication is contraindicated in patients with severe heart problems, liver disease, or a history of allergic reactions to Doxorubicin. It should not be used during pregnancy.

Directions:

Follow the healthcare provider’s instructions carefully when using Doxorubicin. It is important to receive this medication in a medical setting under the supervision of a healthcare professional.

Scientific Evidence:

Studies have shown that Doxorubicin is effective in treating a wide range of cancers. Research published in the Journal of Clinical Oncology demonstrated the efficacy of Doxorubicin in combination with other chemotherapy agents in improving survival rates in patients with advanced cancer.

Additional Information:

It is important to monitor cardiac function regularly during Doxorubicin treatment due to the potential for heart-related side effects. Patients may experience temporary hair loss and nausea as common side effects.

Pharmacological Effects: Doxorubicin works by intercalating into DNA strands, preventing cell replication and ultimately leading to cell death. It also generates free radicals that damage the DNA of cancer cells, further contributing to their destruction.

Clinical Trials: Clinical trials have shown that Doxorubicin, when used in combination with other chemotherapy drugs, can significantly improve response rates and overall survival in patients with various types of cancer. A study published in the New England Journal of Medicine highlighted the benefits of Doxorubicin-based regimens in the treatment of advanced sarcomas.